Market Overview

ProtoKinetix AAGP® Molecule Moving Forward in Key Healthcare Studies Targeting Important Health Care Solutions

Share:

ProtoKinetix, Incorporated (www.protokinetix.com)
(the "Company" or "ProtoKinetix") (OTCQB: PKTX)
President
and Chief Executive Officer Clarence Smith is pleased at the progress of
the health care applications projects the Company has underway.
According to Mr. Smith "To that end, ProtoKinetix is continuing to
collaborate with some of the most prestigious research institutions. The
Company is focusing on research efforts in areas where our AAGP®
molecule can significantly impact the success of healthcare outcomes."

I
invite you to click on the links below for more detailed information.
The
company plans to introduce video content to its website that will allow
for more detailed updates.

Current projects underway include the following:

1. Solutions for Diabetes
Diabetes study currently in a Phase 1
human trial.
Clinicaltrials.gov
- Islet Transplantation Using PKX-001
.

2. Solutions for blindness from age related macular degeneration
Retinal
Cell Replacement study has started Phase 3.
https://www.protokinetix.com/news/2018/august10/

3. Immunology Studies

a) Cord Blood Stem Cell Storage and Recovery.
b) Cord Blood Stem
Cell Transplantation and Engraftment.
c) Monoclonal Antibodies,
‘study completed'.

https://www.protokinetix.com/news/2018/january10/

4. Solutions Enabling Healthy Survival of Strokes and Heart Attacks
AAGP®
Projects for Cardiac/Heart Research includes:

a) Suppression of doxorubicin toxicity
b) Glucolipotoxity protection
c)
Endoplasmic reticulum stress mediation
d) Ischemic damage repair
e)
Whole heart ex-vivo preservation

Research being conducted under proprietary MTA agreements include:

5. Solutions enabling increased healthy numbers of life saving stem cells
Material
Transfer Agreement ‘A' includes studies for:
https://www.protokinetix.com/news/2018/june13/

a) Cryopreservation of primary mammalian tissue cells
b) Enhancing
the viability of primary mammalian cells
c) Cell lines under
stressed culture conditions

6. Material Transfer Agreement ‘B' includes studies for:
https://www.protokinetix.com/news/2017/june5/

a) Immune Cell Cryopreservation recovery, ‘study completed'

In Our Current Pipeline:

Two studies with an undetermined start dates are Kidney Ischemia and
Liver Perfusion.
The company is actively negotiating material
transfer agreements with other companies for collaborative research
studies.
CEO Clarence Smith notes that the company has adequate
cash on hand for project continuation and company operations for the
near term.

About ProtoKinetix, Incorporated

ProtoKinetix is a molecular biotechnology company that has developed and
patented a family of hyper stable, potent glycopeptides (AAGP®) that
enhance both engraftment and protection of transplanted cells used in
regenerative medicine. Due to the results achieved over the last four
years of testing, the University of Alberta has begun Phase 1 human
clinical trials. Additional studies will be expanded to include whole
organ transplantation and all therapies that are being developed
globally to date; diabetes, retinal degeneration, cardiac repair and
many other degenerative conditions. In addition, we are studying the
potential impact on several cancer therapies.

Cautionary Note Regarding Forward-Looking Statements

The information discussed in this press release includes "forward
looking statements" within the meaning of Section 27A of the Securities
Act of 1933 (the "Securities Act") and Section 21E of the Securities
Exchange Act of 1934 (the "Exchange Act").
All statements, other
than statements of historical facts, included herein concerning, among
other things, planned capital expenditures, future cash flows and
borrowings, pursuit of potential acquisition opportunities, our
financial position, business strategy and other plans and objectives for
future operations, are forward looking statements. These forward looking
statements are identified by their use of terms and phrases such as
"may," "expect," "estimate," "project," "plan," "believe," "intend,"
"achievable," "anticipate," "will," "continue," "potential," "should,"
"could," and similar terms and phrases.
Although we believe that
the expectations reflected in these forward looking statements are
reasonable, they do involve certain assumptions, risks and uncertainties
and are not (and should not be considered to be) guarantees of future
performance.
Among these risks are those set forth in a Form 10-K
filed on February 21, 2017. It is important that each person reviewing
this release understand the significant risks attendant to the
operations of ProtoKinetix. ProtoKinetix disclaims any obligation to
update any forward-looking statement made here.

View Comments and Join the Discussion!